Venetoclax Plus PegC May Overcome Resistance to Prior BCL-2 Inhibitors in R/R AML
The addition of pegcrisantaspase to venetoclax may overcome resistance to prior BCL-2 inhibitor–based regimens for patients with relapsed/refractory AML.
Related Articles
Addition of Dostarlimab to Chemo and Niraparib Maintenance Boosts PFS in Advanced Ovarian Cancer
Adding dostarlimab to chemotherapy and niraparib maintenance improved progression-free survival in first-line advanced ovarian cancer.
The 5th Annual OncoAlert Colloquium
The Year in Review in Oncology 2024 brought to you by some of the Worlds TOP experts!
2025 FDA-AACR Workshop: DPD Deficiency and Weighing Potential Harms
AACR is hosting a workshop with the FDA on January 16, 2025, to discuss the considerations for routine testing of DPD deficiency before treatment with…
Hematopoietic cell transplantation soon after first relapse in acute myeloid leukemia – the PROS
Open access journal of the Ferrata-Storti Foundation, a non-profit organization Open access journal of the Ferrata-Storti Foundation, a non-profit organization Department of Hematologic Oncology and…
Home | Multiple Myeloma Hub
Online resource for healthcare professionals, providing information, news & support relating to multiple myeloma
Home | Lymphoma Hub
Online lymphoma resource for healthcare professionals, providing information, news & support relating to lymphoma, Hodgkin & non Hodgkin disease
Targeting APOBEC3 mutational signatures in breast cancer resistance
Avantika Gupta, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the role of APOBEC3 mutational signatures as biomarkers of poor outcomes in metastatic…
Pooled analysis of two clinical trials investigating triplet regimens in IDH-mutated AML
Jennifer Marvin-Peek, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the results of a pooled analysis of two clinical trials investigating…
Shifting from axillary dissection to targeted axillary surgery after neoadjuvant treatment: the evolving management of occult breast cancer in a monoinstitutional series of 114 patients
Breast Cancer Research and Treatment – The use of neoadjuvant systemic therapy for primary breast cancer can achieve tumor shrinkage, enabling less invasive surgical treatments,…
FDA Grants Accelerated Approval to Encorafenib Plus Cetuximab and Chemo for BRAF V600E+ Metastatic Colorectal Cancer
The FDA has approved encorafenib plus cetuximab and mFOLFOX6 for metastatic colorectal cancer with a BRAF V600E mutation.